Evaluation of antitumor activity of a non-steroidal anti-inflammatory drug, ibuprofen, by a targeted nanoparticulate system

Basit Öğe Kaydı
dc.authorscopusid56622412200
dc.authorscopusid57189064109
dc.authorscopusid6603195583
dc.contributor.authorOzturk N.
dc.contributor.authorKara A.
dc.contributor.authorVural I.
dc.date.accessioned2024-08-04T19:59:23Z
dc.date.available2024-08-04T19:59:23Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study we aimed to develop a new targeted nanoparticulate system to obtain site specific delivery of ibuprofen and to determine its antitumor efficiency. The potential effect of ibuprofen as an antitumor agent was investigated on breast cancer cells based on a targeted delivery system. Ibuprofen was encapsulated to poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles. PLGA nanoparticles were fabricated by nanoprecipitation method and optimized in terms of certain parameters. Then, 520C9 monoclonal antibody (mAb) was chemically conjugated to carboxylic acid end group of PLGA nanoparticles (NPs) that specifically targeted human breast adenocarcinoma cell line (MCF-7). NP-mAb combined Ibuprofen encapsulated formulations were evaluated on characterization of particle size, encapsulation efficiency, drug loading capacity, and antitumor activity. The results demonstrated that optimized Ibuprofenloaded PLGA nanoparticles prepared by nanoprecipitation technique had an ideal particle size and polydispersity index. The encapsulation efficiency of optimized nanoparticles was relatively high, 92.9 ± 9.0%. Also, this system had significantly reduced the cell viability on MCF-7 cell line when compared with free ibuprofen solution at the same concentration. Above all, antibody-conjugated nanoparticles showed lower cell viability (12%) than the non-targeted system. Results indicated that ibuprofen-loaded nanoparticles had significant antitumor activity on MCF-7 cells even at relatively low concentrations. mAb conjugated drug-loaded nanoparticles were successfully fabricated and this system might be a promising approach for delivery of ibuprofen in treatment of breast cancer. © 2017, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.en_US
dc.description.sponsorshipHacettepe Üniversitesi: Unit-THD_2015_6088en_US
dc.description.sponsorshipThis project was supported by Hacettepe University’s Scientific Research Projects Coordination Unit-THD_2015_6088en_US
dc.identifier.endpage52en_US
dc.identifier.issn0326-2383
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85002339009en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage44en_US
dc.identifier.urihttps://hdl.handle.net/11616/90590
dc.identifier.volume36en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherColegio de Farmaceuticos de la Provincia de Buenos Airesen_US
dc.relation.ispartofLatin American Journal of Pharmacyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntitumor activityen_US
dc.subjectIbuprofenen_US
dc.subjectMonoclonal antibodyen_US
dc.subjectNanoparticlesen_US
dc.subjectTargetingen_US
dc.titleEvaluation of antitumor activity of a non-steroidal anti-inflammatory drug, ibuprofen, by a targeted nanoparticulate systemen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu